SCHEDULE: Vanguard Group Exits Revolution Medicines Ownership

The Vanguard Group reports 0% beneficial ownership in REVOLUTION Medicines Inc following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 4 to Schedule 13G for REVOLUTION Medicines Inc.
• The filing indicates that The Vanguard Group now beneficially owns 0.00 shares, representing 0% of the class of Common Stock.
• This change is due to an internal realignment within The Vanguard Group, Inc. on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard will report beneficial ownership separately.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over these securities.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative development for REVOLUTION Medicines Inc, as a prominent institutional investor no longer reports beneficial ownership, even though the reason is an internal realignment at Vanguard.

Negatives

• The Vanguard Group, a significant institutional investor, no longer reports beneficial ownership in REVOLUTION Medicines Inc.

Future Outlook

This administrative filing does not contain any forward-looking statements or guidance regarding REVOLUTION Medicines Inc's future performance or operations.

Management Comments

• The Vanguard Group, Inc. went through an internal realignment on January 12, 2026, leading to certain subsidiaries or business divisions reporting beneficial ownership separately.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that this filing primarily reflects an internal organizational change within The Vanguard Group rather than a direct commentary on REVOLUTION Medicines Inc's industry position or performance. While the reduction to 0% beneficial ownership by Vanguard is notable, it stems from a structural shift in reporting rather than a divestment based on the issuer's fundamentals.

Stakeholder Impact

• Shareholders of REVOLUTION Medicines Inc may note the change in reported institutional ownership, potentially influencing market perception.

Key Dates

Recommendation

This filing is administrative, detailing an internal realignment within The Vanguard Group that resulted in their reported beneficial ownership of REVOLUTION Medicines Inc dropping to 0%. While not a direct divestment based on the issuer's performance, the absence of a major institutional holder from the 13G can be a minor negative signal. Without further fundamental information on REVOLUTION Medicines Inc, a 'hold' recommendation is prudent, advising investors to monitor future filings and company performance.

Keywords

REVOLUTION Medicines Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Ownership, Common Stock, SEC Filing, Investment Management